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In animals, thiazolidinediones reduce ischaemia-
reperfusion injury. A clinical meta-analysis raised
suspicion that rosiglitazone increases the incidence
of myocardial infarction (Nissen et al., N Engl J Med
2007;356:2457–2471). However, human data
on a possible benefit on infarct size (i.e.
ischaemia-reperfusion injury) are not available.
Therefore, we investigated the effect of rosiglita-
zone on ischaemia-reperfusion injury in 10
insulin resistant participants without hyperglycae-
mia. We used a thoroughly validated human in
vivo model to quantify ischaemia-reperfusion
injury in skeletal muscle by annexin-A5-
scintigraphy (Rongen et al., Circulation 2005;111:
173–178). At the end of each treatment period
(rosiglitazone 4 mg b.d. vs. placebo), the partici-
pants were subjected to 10 min of forearm ischae-
mia, combined with standardized intermittent
handgripping. At reperfusion, 500 MBq
99mTc-annexin-A5 was administered intrave-
nously. Annexin-uptake (counts per pixel) was
measured in thenar muscle 1 h post-reperfusion
using a gamma camera. Ischaemia-reperfusion
injury was quantified as the percentage difference in uptake between experimental and control side (annexin-targeting). Rosiglitazone
reduced annexin-targeting from 8.4% (median; range 0.6–49%) to 4.7% (0.7–20%) (P ¼ 0.037). We present the first human in vivo data
on the beneficial effects of rosiglitazone on ischaemia-reperfusion injury. This observation puts the disputed elevation in myocardial
ischaemic events during rosiglitazone treatment in perspective.
Panel A. Study design.
Panel B. Individual plots of the effects of rosiglitazone on 99mTc-annexin-targeting in insulin resistant subjects.
Panel C. Typical 99mTc-annexin-uptake one hour after reperfusion at the end of the placebo period. Left: control hand; right: post-
ischaemic hand. Counts increase from blue to yellow.
Panel D. Same patient, but at the end of the rosiglitazone treatment period.
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